These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 9065577)
1. Expression of P-glycoprotein in high grade osteosarcomas with special emphasis on chondroblastic subtype. Radig K; Häckel C; Herting J; Oda Y; Mittler U; Neumann W; Roessner A Gen Diagn Pathol; 1997 Feb; 142(3-4):139-45. PubMed ID: 9065577 [TBL] [Abstract][Full Text] [Related]
2. Expression of c-met proto-oncogene product (c-MET) in benign and malignant bone tumors. Naka T; Iwamoto Y; Shinohara N; Ushijima M; Chuman H; Tsuneyoshi M Mod Pathol; 1997 Aug; 10(8):832-8. PubMed ID: 9267827 [TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy. Baldini N; Scotlandi K; Serra M; Picci P; Bacci G; Sottili S; Campanacci M J Orthop Res; 1999 Sep; 17(5):629-32. PubMed ID: 10569469 [TBL] [Abstract][Full Text] [Related]
4. May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol. Serra M; Pasello M; Manara MC; Scotlandi K; Ferrari S; Bertoni F; Mercuri M; Alvegard TA; Picci P; Bacci G; Smeland S Int J Oncol; 2006 Dec; 29(6):1459-68. PubMed ID: 17088985 [TBL] [Abstract][Full Text] [Related]
5. P-glycoprotein expression in high grade central osteosarcoma and normal bone cells. An immunohistochemical study. Pösl M; Amling M; Grahl K; Hentz M; Ritzel H; Werner M; Winkler K; Delling G Gen Diagn Pathol; 1997 Jun; 142(5-6):317-25. PubMed ID: 9228255 [TBL] [Abstract][Full Text] [Related]
6. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma. Oda Y; Sakamoto A; Shinohara N; Ohga T; Uchiumi T; Kohno K; Tsuneyoshi M; Kuwano M; Iwamoto Y Clin Cancer Res; 1998 Sep; 4(9):2273-7. PubMed ID: 9748149 [TBL] [Abstract][Full Text] [Related]
7. The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis. Pakos EE; Ioannidis JP Cancer; 2003 Aug; 98(3):581-9. PubMed ID: 12879476 [TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma. Kilpatrick SE; Geisinger KR; King TS; Sciarrotta J; Ward WG; Gold SH; Bos GD Mod Pathol; 2001 Dec; 14(12):1277-83. PubMed ID: 11743051 [TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Bacci G; Bertoni F; Longhi A; Ferrari S; Forni C; Biagini R; Bacchini P; Donati D; Manfrini M; Bernini G; Lari S Cancer; 2003 Jun; 97(12):3068-75. PubMed ID: 12784343 [TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor expression in high-grade osteosarcomas is associated with a good clinical outcome. Kersting C; Gebert C; Agelopoulos K; Schmidt H; van Diest PJ; Juergens H; Winkelmann W; Kevric M; Gosheger G; Brandt B; Bielack S; Buerger H Clin Cancer Res; 2007 May; 13(10):2998-3005. PubMed ID: 17505002 [TBL] [Abstract][Full Text] [Related]
11. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. Baldini N; Scotlandi K; Barbanti-Bròdano G; Manara MC; Maurici D; Bacci G; Bertoni F; Picci P; Sottili S; Campanacci M N Engl J Med; 1995 Nov; 333(21):1380-5. PubMed ID: 7477118 [TBL] [Abstract][Full Text] [Related]
12. Expression of vascular endothelial growth factor-C and its receptor in osteosarcomas. Park HR; Min K; Kim HS; Jung WW; Park YK Pathol Res Pract; 2008; 204(8):575-82. PubMed ID: 18440723 [TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma. Ferrari S; Zanella L; Alberghini M; Palmerini E; Staals E; Bacchini P Pediatr Blood Cancer; 2008 Apr; 50(4):752-6. PubMed ID: 17886294 [TBL] [Abstract][Full Text] [Related]
14. Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group. Schwartz CL; Gorlick R; Teot L; Krailo M; Chen Z; Goorin A; Grier HE; Bernstein ML; Meyers P; J Clin Oncol; 2007 May; 25(15):2057-62. PubMed ID: 17513810 [TBL] [Abstract][Full Text] [Related]
15. Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure. Goff BA; Ries JA; Els LP; Coltrera MD; Gown AM Gynecol Oncol; 1998 Sep; 70(3):378-85. PubMed ID: 9790791 [TBL] [Abstract][Full Text] [Related]
16. [Primary chemotherapy with the Rosen T10 protocol before conservative surgery in limb primitive osteosarcomas: results about 56 cases]. Boussen H; Mezzi F; Gamoudi A; Daldoul O; Ben Hamida H; Mezlini A; Khalfallah S; Karray S; Ben Romdhane K; Ben Ghachem M; Ben Abdallah M; Douik M; Saadi A; Ben Ayed F; Ben Hassine H Bull Cancer; 2000 Feb; 87(2):183-8. PubMed ID: 10705289 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma. Ferrari S; Bertoni F; Zanella L; Setola E; Bacchini P; Alberghini M; Versari M; Bacci G Cancer; 2004 May; 100(9):1936-42. PubMed ID: 15112275 [TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Kaya M; Wada T; Akatsuka T; Kawaguchi S; Nagoya S; Shindoh M; Higashino F; Mezawa F; Okada F; Ishii S Clin Cancer Res; 2000 Feb; 6(2):572-7. PubMed ID: 10690541 [TBL] [Abstract][Full Text] [Related]